Inducible phosphofructokinase and the Warburg effect
AssigneeThe Picower Institute for Medical Research
InventorsRichard J. Bucala, Jason Chesney, Robert A. Mitchell
Life of this patent
Estimating the term…
Abstract
There is disclosed a cancer malignancy diagnostic assay comprising obtaining a sample of a body fluid or tissue, performing a sequence identity assay to look for the presence of PFK-2 specific sequences; an anticancer pharmaceutical composition comprising a specific antisense oligonucleotide to the inventive isolated PFK-2 sequence and a pharmaceutically acceptable oligonucleotide carrier; and a method for finding therapeutically active anti-cancer compounds comprising screening compounds for activity to inhibit PFK-2 but not PFK.
Claims10
An anticancer pharmaceutical composition comprising a specific antisense oligonucleotide of at least 10 bases to the iPFK-2 cDNA sequence [SEQ ID NO. 11] and a pharmaceutically acceptable oligonucleotide carrier.
An anti-inflammatory pharmaceutical composition comprising a specific antisense oligonucleotide of at least 10 bases to the iPFK-2 cDNA sequence [SEQ ID NO. 11] and a pharmaceutically acceptable oligonucleotide carrier.
An antisense oligonucleotide of at least 10 bases complementary to the iPFK-2 cDNA sequence [SEQ ID NO. 11].
A method for treating inflammatory diseases, comprising administering an effective amount of an iPFK-2 antagonist.
A method for treating rapidly-growing cancers, comprising administering an effective amount of an iPFK-2 antagonist.
Dependencies are inferred from the claim text.